Docking-Based Classification Models for Exploratory Toxicology Studies on High-Quality Estrogenic Experimental Data

References

• Merlot C . Computational toxicology – a tool for early safety evaluation. Drug Discov. Today15 (1–2), 16–22 (2010).
   PubMed Web of Science ®Google Scholar
• Kavlock R , DixD. Computational toxicology as implemented by the U.S. EPA: providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk. J. Toxicol. Environ. Health Part B13 (2–4), 197–217 (2010).
   PubMed Web of Science ®Google Scholar
• Nicolotti O , BenfenatiE, CarottiAet al. REACH and in silico methods: an attractive opportunity for medicinal chemists. Drug Discov. Today19 (11), 1757–1768 (2014).
   PubMed Web of Science ®Google Scholar
• Judson R , RichardA, DixDJet al. The toxicity data landscape for environmental chemicals. Environ. Health Perspect.117 (5), 685–695 (2009).
   PubMed Web of Science ®Google Scholar
• Judson R , RichardA, DixDet al. ACToR – aggregated computational toxicology resource. Toxicol. Appl. Pharmacol.233 (1), 7–13 (2008).
   PubMed Web of Science ®Google Scholar
• European Commission . Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC. J. Eur. Union Lett.396, 1–849 (2006).
   Google Scholar
• Van Heerden S . Recent developments in global regulatory framework in the chemical industry. Popul. Plast. Packag.57, 46–50 (2012).
   Google Scholar
• Diamanti-Kandarakis E , BourguignonJP, GiudiceLCet al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr. Rev.30 (4), 293–342 (2009).
   PubMed Web of Science ®Google Scholar
• Shi LM , FangH, TongWet al. QSAR models using a large diverse set of estrogens. J. Chem. Inf. Comput. Sci.41 (1), 186–195 (2000).
   Google Scholar
• Devillers J , Marchand-GenesteN, CarpyA, PorcherJM. SAR and QSAR modeling of endocrine disruptors. SAR QSAR Environ. Res.17 (4), 393–412 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobs MN . In silico tools to aid risk assessment of endocrine disrupting chemicals. Toxicology205 (1–2), 43–53 (2004).
   PubMed Web of Science ®Google Scholar
• Organization for Economic Cooperation and Development. www.qsartoolbox.org
   Google Scholar
• Nicolotti O , GiangrecoI, MisciosciaTF, CarottiA. Improving quantitative structure–activity relationships through multiobjective optimization. J. Chem. Inf. Model.49 (10), 2290–2302 (2009).
   PubMed Web of Science ®Google Scholar
• Nicolotti O , MisciosciaTF, CarottiA, LeonettiF, CarottiA. An integrated approach to ligand- and structure-based drug design: development and application to a series of serine protease inhibitors. J. Chem. Inf. Model.48 (6), 1211–1226 (2008).
   PubMed Web of Science ®Google Scholar
• Kitchen DB , DecornezH, FurrJR, BajorathJ. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov.3 (11), 935–949 (2004).
   PubMed Web of Science ®Google Scholar
• Shoichet BK . Virtual screening of chemical libraries. Nature432 (7019), 862–865 (2004).
   PubMed Web of Science ®Google Scholar
• Kolšek K , MavriJ, Sollner DolencM, GobecS, TurkS. Endocrine disruptome – an open source prediction tool for assessing endocrine disruption potential through nuclear receptor binding. J. Chem. Inf. Model.54 (4), 1254–1267 (2014).
   PubMed Web of Science ®Google Scholar
• Mueller SO , KorachKS. Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice. Curr. Opin. Pharmacol.1 (6), 613–619 (2001).
   PubMedGoogle Scholar
• Shanle EK , XuW. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action. Chem. Res. Toxicol.24 (1), 6–19 (2011).
   PubMed Web of Science ®Google Scholar
• Colborn T . Environmental estrogens: Health implications for humans and wildlife. Environ. Health Perspect.103 (Suppl. 7), 135–136 (1995).
   PubMedGoogle Scholar
• Muegge I , OloffS. Advances in virtual screening. Drug Discov. Today Technol.3 (4), 405–411 (2006).
   Google Scholar
• Ma XH , ZhuF, LiuXet al. Virtual screening methods as tools for drug lead discovery from large chemical libraries. Curr. Med. Chem.19 (32), 5562–5571 (2012).
   PubMed Web of Science ®Google Scholar
• Gissi A , GadaletaD, FlorisMet al. An alternative QSAR-based approach for predicting the bioconcentration factor for regulatory purposes. ALTEX31 (1), 23–36 (2014).
   PubMedGoogle Scholar
• Fourches D , MuratovE, TropshaA. Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. J. Chem. Inf. Model.50 (7), 1189–1204 (2010).
   PubMed Web of Science ®Google Scholar
• Small-Molecule Drug Discovery Suite 2014–4: GLIDE, version 6.5, Schrödinger, LLC, New York, NY, 2014.
   Google Scholar
• Jones G , WillettP, GlenRC, LeachAR, TaylorR. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol.267 (3), 727–748 (1997).
   PubMed Web of Science ®Google Scholar
• Hornberg JJ , LaursenM, BrendenNet al. Exploratory toxicology as an integrated part of drug discovery. Part I: why and how. Drug Discov. Today19 (8), 1131–1136 (2014).
   PubMed Web of Science ®Google Scholar
• Zhang L , SedykhA, TripathiAet al. Identification of putative estrogen receptor-mediated endocrine disrupting chemicals using QSAR- and structure-based virtual screening approaches. Toxicol. Appl. Pharmacol.272 (1), 67–76 (2013).
   PubMed Web of Science ®Google Scholar
• Heldring N , PikeA, AnderssonSet al. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev.87 (3), 905–931 (2007).
   PubMed Web of Science ®Google Scholar
• Shiau AK , BarstadD, RadekJTet al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat. Struct. Mol. Biol.9 (5), 359–364 (2002).
   Google Scholar
• Tanenbaum DM , WangY, WilliamsSP, SiglerPB. Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc. Natl Acad. Sci. USA95 (11), 5998–6003 (1998).
   PubMed Web of Science ®Google Scholar
• Fang J , Akwabi-AmeyawA, BrittonJEet al. Synthesis of 3-alkyl naphthalenes as novel estrogen receptor ligands. Bioorg. Med. Chem. Lett.18 (18), 5075–5077 (2008).
   PubMed Web of Science ®Google Scholar
• Kim S , WuJY, BirzinETet al. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor α modulators. J. Med. Chem.47 (9), 2171–2175 (2004).
   PubMed Web of Science ®Google Scholar
• Möcklinghoff S , RoseR, CarrazM, VisserA, OttmannC, BrunsveldL. Synthesis and crystal structure of a phosphorylated estrogen receptor ligand binding domain. Chem. Biol. Chem.11 (16), 2251–2254 (2010).
   Google Scholar
• Mewshaw RE , BowenSM, HarrisHA, XuZB, ManasES, CohnST. ERbeta ligands. Part 5: synthesis and structure–activity relationships of a series of 4′-hydroxyphenyl-aryl-carbaldehyde oxime derivatives. Bioorg. Med. Chem. Lett.17 (4), 902–906 (2007).
   PubMed Web of Science ®Google Scholar
• Pike AC , BrzozowskiAM, HubbardREet al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J.18 (17), 4608–4618 (1999).
   PubMed Web of Science ®Google Scholar
• Schrödinger Release 2014–4: LigPrep, version 3.2, Schrödinger, LLC, New York, NY, 2014.
   Google Scholar
• Schrödinger Release 2014–4: Schrödinger Suite 2014–4 Protein Preparation Wizard; Epik version 3.0, Schrödinger, LLC, New York, NY, 2014; Impact version 6.5, Schrödinger, LLC, New York, NY, 2014; Prime version 3.8, Schrödinger, LLC, New York, NY, 2014..
   Google Scholar
• Banks JL , BeardHS, CaoYet al. Integrated modeling program, applied chemical theory (IMPACT). J. Comput. Chem.26 (16), 1752–1780 (2005).
   PubMed Web of Science ®Google Scholar
• Schapira M , AbagyanR, TotrovM. Nuclear hormone receptor targeted virtual screening. J. Med. Chem.46 (14), 3045–3059 (2003).
   PubMed Web of Science ®Google Scholar
• Klebe G . Virtual ligand screening: strategies, perspectives and limitations. Drug Discov. Today11 (13–14), 580–594 (2006).
   PubMed Web of Science ®Google Scholar
• Huang N , ShoichetBK, IrwinJJ. Benchmarking sets for molecular docking. J. Med. Chem.49 (23), 6789–6801 (2006).
   PubMed Web of Science ®Google Scholar
• Nam K , MarshallP, WolfRM, CornellW. Simulation of the different biological activities of diethylstilbestrol (DES) on estrogen receptor alpha and estrogen-related receptor gamma. Biopolymers68 (1), 130–138 (2003).
   PubMed Web of Science ®Google Scholar
• Walker VR , JeffersonWN, CouseJF, KorachKS. Estrogen receptor-α mediates diethylstilbestrol-induced feminization of the seminal vesicle in male mice. Environ. Health Perspect.120 (4), 560–565 (2012).
   PubMed Web of Science ®Google Scholar
• Sikoski P , RegisterTC, LeesCJet al. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (macaca fascicularis). Am. J. Obstet. Gynecol.196 (1), 75.e1–75.e7 (2007).
   PubMed Web of Science ®Google Scholar
• Shiau AK , BarstadD, LoriaPMet al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell95 (7), 927–937 (1998).
   PubMed Web of Science ®Google Scholar
• Yin L , HuQ. Drug discovery for breast cancer and co-instantaneous cardiovascular disease: what is the future?Future Med. Chem.5 (4), 359–362 (2013).
   PubMed Web of Science ®Google Scholar
• Barkhem T , CarlssonB, NilssonY, EnmarkE, GustafssonJ, NilssonS. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol.54 (1), 105–112 (1998).
   PubMed Web of Science ®Google Scholar
• Dinwiddie MT , TerryPD, ChenJ. Recent evidence regarding triclosan and cancer risk. Int. J. Environ. Res. Public Health.11 (2), 2209–2217 (2014).
   PubMed Web of Science ®Google Scholar
• Geens T , AertsD, BerthotCet al. A review of dietary and non-dietary exposure to bisphenol-A. Food Chem. Toxicol.50 (10), 3725–3740 (2012).
   PubMed Web of Science ®Google Scholar
• Rastogi SC , SchoutenA, de KruijfN, WeijlandJW. Contents of methyl-, ethyl-, propyl-, butyl- and benzylparaben in cosmetic products. Contact Dermatitis.32 (1), 28–30 (1995).
   PubMed Web of Science ®Google Scholar
• Bowers JL , TyulmenkovVV, JerniganSC, KlingeCM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β. Endocrinology141 (10), 3657–3667 (2000).
   PubMed Web of Science ®Google Scholar
• Fuller HR , HumphreyEL, MorrisGE. Naturally occurring plant polyphenols as potential therapies for inherited neuromuscular diseases. Future Med. Chem.5 (17), 2091–2101 (2013).
   PubMed Web of Science ®Google Scholar
• Huang H , DuG, ZhangWet al. The in vitro estrogenic activities of triclosan and triclocarban. J. Appl. Toxicol.34 (9), 1060–1067 (2014).
   PubMed Web of Science ®Google Scholar
• Okubo T , YokoyamaY, KanoK, KanoI. ER-dependent estrogenic activity of parabens assessed by proliferation of human breast cancer MCF-7 cells and expression of ERα and PR. Food Chem. Toxicol.39 (12), 1225–1232 (2001).
   PubMed Web of Science ®Google Scholar